Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Neutrolis, Remora Therapeutics
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today announced that Neutrolis and Remora Therapeutics are the winners of Bristol-Myers Squibb's 2017 Golden Tickets for LabCentral. As a platinum sponsor of LabCentral, Bristol-Myers Squibb can select up to two innovative life-sciences and biotech startup companies per year of active sponsorship for "Golden Tickets,"
AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China
- Details
- Category: AstraZeneca
AstraZeneca today announced a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China to discover, develop and commercialise potential new medicines to help meet unmet needs globally, and to bring innovative new medicines to patients in China faster.
Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
- Details
- Category: Novartis
Novartis today announced positive results from the FLASH** study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD) patients from Seretide® (salmeterol/fluticasone) 50/500 mcg to Ultibro® Breezhaler® (indacaterol/glycopyrronium) 110/50 mcg[1]. The study met the primary endpoint demonstrating that switching patients to Ultibro Breezhaler resulted in significantly improved lung function (trough FEV1)[1].
GSK submits landmark IMPACT data to US regulatory authority to support expanded label for Trelegy Ellipta
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, 'FF/UMEC/VI') for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Boehringer Ingelheim makes many of its best molecules openly available to the scientific community via opnMe.com to unlock their full potential
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnME.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and collaborative discovery as well as the identification of novel treatment approaches for patients.
Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced an agreement with Viewics, Inc., a privately held software company focused on laboratory business analytics. Under the agreement, Roche is acquiring all shares of the company. The acquisition, which is subject to customary closing conditions, is expected to close on November 21, 2017.
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
- Details
- Category: Novartis
Novartis, the American Society for Clinical Pathology (ASCP) and the American Cancer Society (ACS) will work together to devise a common approach to improve access to cancer treatment in Sub-Saharan Africa. Each partner brings unique expertise in cancer diagnosis and treatment. This complements the work the Clinton Health Access Initiative (CHAI) is doing to improve access to affordable, quality-approved oncology medicines in the region.
More Pharma News ...
- Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
- Pfizer receives FDA approval for SUTENT® (sunitinib malate) as first and only adjuvant treatment for adult patients at high risk of recurrent renal cell carcinoma
- Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma
- New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure
- BMS-Pfizer Alliance to unveil real-world data analyses - cost, safety and comparative effectiveness findings associated with oral anticoagulants in non-valvular atrial fibrillation
- Boehringer Ingelheim and MiNA Therapeutics to develop novel treatment approaches for fibrotic liver diseases
- Sanofi, Principia agree to develop multiple sclerosis drug candidate